Akebia Ther is a drug manufacturers - specialty & generic business based in the US. Akebia Ther shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.13 – a decrease of 11.25% over the previous week. Akebia Ther employs 181 staff and has a trailing 12-month revenue of around $160.2 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – AKBA.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Akebia Ther stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Akebia Ther stock price (NASDAQ: AKBA)
Use our graph to track the performance of AKBA stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Akebia Ther price performance over time
Historical closes compared with the close of $2.13 from 2025-03-21
1 week (2025-03-17)
-11.25%
1 month (2025-02-24)
20.34%
3 months (2024-12-24)
14.52%
6 months (2024-09-24)
57.78%
1 year (2024-03-22)
-1.84%
2 years (2023-03-24)
233.44%
3 years (2022-03-24)
2.5
5 years (2020-03-24)
7.24
Akebia Ther financials
Revenue TTM
$160.2 million
Gross profit TTM
$134 million
Return on assets TTM
-12.49%
Return on equity TTM
-553.45%
Profit margin
-43.33%
Book value
$-0.22
Market Capitalization
$556.4 million
TTM: trailing 12 months
Akebia Ther share dividends
We're not expecting Akebia Ther to pay a dividend over the next 12 months.
Akebia Ther share price volatility
Over the last 12 months, Akebia Ther's shares have ranged in value from as little as $0.8 up to $2.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Ther's is 0.944. This would suggest that Akebia Ther's shares are less volatile than average (for this exchange).
Akebia Ther overview
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. The company has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
null What percentage of Akebia Ther is owned by insiders or institutions? Currently 4.449% of Akebia Ther shares are held by insiders and 28.901% by institutions.How many people work for Akebia Ther? Latest data suggests 181 work at Akebia Ther.When does the fiscal year end for Akebia Ther? Akebia Ther's fiscal year ends in December.Where is Akebia Ther based? Akebia Ther's address is: 245 First Street, Cambridge, MA, United States, 02142What is Akebia Ther's ISIN number? Akebia Ther's international securities identification number is: US00972D1054What is Akebia Ther's CUSIP number? Akebia Ther's Committee on Uniform Securities Identification Procedures number is: 00972D105
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
